N/A N=41 Tobacco Treatment in the Context of Lung Cancer Screening
Smoking Cessation
Primary: End of Treatment Abstinence Rates — 3; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=103 Individualizing Treatment for Asthma in Primary Care
Asthma · Bronchial Diseases · Respiratory Tract Infections
Primary: Asthma Control as Measured by the Asthma Control Test (ACT) — 18.77; 18.96; 20.45; 20.14 units on a scale
Phase 3 N=391 Maternal Depression Treatment in HIV
Depression
Primary: Rate of Maternal HIV Viral Suppression — 128; 132 Participants
N/A N=26 Environmental Treatment for Seasonal Affective Disorder (SAD)
Seasonal Affective Disorder
Primary: Percentage SIGH SAD (Structured Interview Guide For The Hamilton Depression Rating Scale), SAD Version — 34.5; 60.4 Percentage of SIGH SAD — p=0.028
N/A N=169 Brief Treatment for Posttraumatic Stress Disorder
PTSD
Primary: Clinician Administered PTSD Scale, 5 (CAPS-5) — 31.55; 25.12; 29.59; 25.41 score on a scale
N/A N=30 HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2
Major Depressive Disorder · Depression
Primary: Net Promoter Score, and Enrollment Likelihood — 7.73; 8.00; 4.13; 4.29 score on a scale
Phase 2 N=16 Treatment for Migraine and Mood (Team-M)
Migraine · Depression
Primary: Treatment Session Adherence Rate — 7.88; 8 Number of sessions attended
Phase 4 N=188 Treatment for Post-Stroke Depression
Stroke · Depression
Primary: Twelve Week Depression Outcomes — 10.6 HAM-D depression score
N/A N=95 Adolescent Depression Screening and Treatment in Mozambican Primary Care
Depression · Adolescent Behavior
Primary: Change in PHQ-A Score From Baseline to 6 Months Post-intervention — -35.9; -54.0 percent change
N/A N=384 Post-resection Treatment of Large Colon Polyps
Recurrence
Primary: Recurrence — 10; 5; 24 Polyps
N/A N=120 Specialized Treatment Early in Psychosis (STEP)
Schizophrenia and Disorders With Psychotic Features
Primary: Number of Patients Hospitalized — 25; 14 participants — p=0.018
N/A N=85 Treatment for Affect Dimensions
Depression · Anxiety
Primary: Positive Affect Subscale of the Positive and Negative Affect Scale (PANAS-P) — 20.76; 29.42; 24.18; 19.42 score on a scale — p=.002
N/A N=104 Start Treatment and Recovery for Opioid Use Disorder
Opioid-use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Primary: Number of Participants With Self-reported Treatment Retention — 51 Participants
Phase 3 N=699 Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
Diabetes Mellitus, Type II
Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants
Phase 4 N=700 Sequenced Treatment Effectiveness for Posttraumatic Stress
PTSD
Primary: PTSD Symptoms — 39.3; 38.6; 40.5 units on a scale
N/A N=141 Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Pulmonary Disease, Chronic Obstructive · Major Depression
Primary: Composite Antidepressant Score Scale (CAD) — 29; 25; 9; 20 Participants
N/A N=216 Treatment Advocacy Intervention for HIV-Positive African Americans
HIV
Primary: Medication Adherence — 77.96; 80.13; 64.87; 76.13 Percentage of doses taken — p=.005
N/A N=30 Treatments for Improving Mood in Depressed Teens-3
Depression
Primary: Acceptability — 11; 13 Participants
N/A N=37 A Unified Treatment for Anxiety Disorders
Emotional Disorders · Anxiety Disorders
Primary: Anxiety Disorders Interview Schedule for DSM-IV — 5.23; 5.09; 3.18; 5.14 score on a scale
Phase 4 N=41 Sequencing Treatments for Mothers With ADHD and Their At - Risk Children
Attention Deficit Hyperactivity Disorder
Primary: Child Behavioral Functioning — 4.78; 4.56; 4.44; 4.67 units on a scale
N/A N=554 COVID-19 Treatment Cascade Optimization Study
COVID-19
Primary: Completion of COVID-19 Test — 72; 60 Participants
N/A N=100 Mental Health Services for Prisoners With SMI
Mental Disorder
Primary: Change in Levels of Aggression Score From Baseline to Month 3 — -4.81; -2.68 score on a scale
N/A N=182 Rapid HCV Treatment Access for Persons Who Use Drugs
Hepatitis C Virus Infection, Response to Therapy of
Primary: Participants Who Initiate HCV Therapy — 59; 12 Participants — p=<0.001
Phase 4 N=222 Interventions for Children With Attention and Reading Disorders
Attention Deficit Hyperactivity Disorder · Reading Disabilities
Primary: Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Inattention — 1.1; 1.7; 1.0; 1.3 Units on a scale
Phase 1 N=99 CBT With Disulfiram and Contingency Management
Cocaine Abuse
Primary: Change in Cocaine Use by Self Report — 72.2; 79.2; 91.1; 69.6 percentage of days abstinent
N/A N=154 Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Primary: Social Behavior-Negative Verbalizations — 73.32; 45.41; 28.41; 15.08 Number of Observed Behaviors
N/A N=169 European Study on Three Different Approaches to Managing Class 2 Cavities in Primary Teeth
Dental Caries
Primary: Failure Rate of the Three Treatment Arms Judged Clinically — 37; 31; 39; 2 Teeth — p=0.02
Phase 4 N=1,275 Study of Oral Treatments for Hepatitis C
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR12) mITT With Imputation-Phase 1 and 2 EBR/GZR, SOF/LDV — 40; 516; 14; 335 Participants
N/A N=196 Prevention and Risk: Treatment With a New Emphasis on Relationships
Adherence, Medication · Risk Reduction · Drug Use
Primary: Illicit Drug Use Days — 1.49; .80; 1.16; 0.83 days — p=.433
N/A N=13 Tx for Child Sexual Behavior Problems
Sexual Behavior
Primary: Child Sexual Behavior on the Child Sexual Behavior Inventory (CSBI) — 28.8; 18.1 Scores on a scale